Obefazimod for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease by a colonoscopy and biopsy.
- Your Crohn's is moderate to severe, meaning you have certain symptoms and inflammation seen on a colonoscopy.
- You have tried at least one standard treatment (like steroids, immunosuppressants, or a biologic) and it didn't work well enough or you couldn't take it.
- You do not have an active infection, a colostomy bag, or a history of certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
Hear when a new Moderately to Severely Active Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.